CA Patent

CA2621545A1 — Ramipril formulation

Assigned to Selamine Ltd · Expires 2007-03-15 · 19y expired

What this patent protects

A Ramipril formulation rapidly disintegrates after ingestion and exhibits substantially no food effect.

USPTO Abstract

A Ramipril formulation rapidly disintegrates after ingestion and exhibits substantially no food effect.

Drugs covered by this patent

Patent Metadata

Patent number
CA2621545A1
Jurisdiction
CA
Classification
—
Expires
2007-03-15
Drug substance claim
No
Drug product claim
No
Assignee
Selamine Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.